Do analysts prefer IBAC or BNGO?

Bionano Genomics has a consensus target price of $6.00, suggesting a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than IB Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IB Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation & earnings, IBAC or BNGO?

IB Acquisition has higher earnings, but lower revenue than Bionano Genomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IB Acquisition N/A N/A N/A N/A N/A Bionano Genomics $28.51M 0.50 -$26.40M -$3.02 N/A

Do analysts recommend BNGO or BFRG?

Bionano Genomics presently has a consensus price target of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts plainly believe Bionano Genomics is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Bullfrog AI 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BNGO or BFRG more profitable?

Bullfrog AI has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. Bionano Genomics' return on equity of -78.78% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Bionano Genomics -106.58% -78.78% -48.54% Bullfrog AI N/A -150.36% -127.98%

Do analysts prefer VIVS or BNGO?

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts clearly believe Bionano Genomics is more favorable than VivoSim Labs. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is VIVS or BNGO more profitable?

Bionano Genomics has a net margin of -106.58% compared to VivoSim Labs' net margin of -11,016.07%. Bionano Genomics' return on equity of -78.78% beat VivoSim Labs' return on equity. Company Net Margins Return on Equity Return on Assets VivoSim Labs -11,016.07% -612.23% -177.02% Bionano Genomics -106.58% -78.78% -48.54%

Do analysts prefer BNGO or ISPC?

Bionano Genomics presently has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts plainly believe Bionano Genomics is more favorable than iSpecimen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bionano Genomics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 iSpecimen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BNGO or ISPC more profitable?

Bionano Genomics has a net margin of -106.58% compared to iSpecimen's net margin of -2,445.40%. Bionano Genomics' return on equity of -78.78% beat iSpecimen's return on equity. Company Net Margins Return on Equity Return on Assets Bionano Genomics -106.58% -78.78% -48.54% iSpecimen -2,445.40% -524.39% -140.42%

Bionano Genomics (BNGO) Competitors

$1.20 -0.04 (-3.23%)

As of 04:00 PM Eastern

Compare

BNGO vs. IBAC, HBIO, BFRG, VIVS, and ISPC

Should you buy Bionano Genomics stock or one of its competitors? Bionano Genomics's main competitors and comparable companies include IB Acquisition (IBAC), Harvard Bioscience (HBIO), Bullfrog AI (BFRG), VivoSim Labs (VIVS), and iSpecimen (ISPC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Bionano Genomics compare to IB Acquisition?

IB Acquisition (NASDAQ:IBAC) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

IB Acquisition has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. IB Acquisition's return on equity of 0.00% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IB Acquisition	N/A	N/A	N/A
Bionano Genomics	-106.58%	-78.78%	-48.54%

Bionano Genomics has a consensus target price of $6.00, suggesting a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts plainly believe Bionano Genomics is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, IB Acquisition had 1 more articles in the media than Bionano Genomics. MarketBeat recorded 1 mentions for IB Acquisition and 0 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 0.00 beat IB Acquisition's score of -0.71 indicating that Bionano Genomics is being referred to more favorably in the news media.

Company	Overall Sentiment
IB Acquisition	Negative
Bionano Genomics	Neutral

11.4% of Bionano Genomics shares are held by institutional investors. 0.7% of Bionano Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

IB Acquisition has higher earnings, but lower revenue than Bionano Genomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IB Acquisition	N/A	N/A	N/A	N/A	N/A
Bionano Genomics	$28.51M	0.50	-$26.40M	-$3.02	N/A

Summary

Bionano Genomics beats IB Acquisition on 7 of the 11 factors compared between the two stocks.

How does Bionano Genomics compare to Harvard Bioscience?

Harvard Bioscience (NASDAQ:HBIO) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Harvard Bioscience has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.65, suggesting that its stock price is 65% more volatile than the broader market.

In the previous week, Harvard Bioscience had 1 more articles in the media than Bionano Genomics. MarketBeat recorded 1 mentions for Harvard Bioscience and 0 mentions for Bionano Genomics. Harvard Bioscience's average media sentiment score of 0.00 equaled Bionano Genomics'average media sentiment score.

Company	Overall Sentiment
Harvard Bioscience	Neutral
Bionano Genomics	Neutral

80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 17.0% of Harvard Bioscience shares are owned by company insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Bionano Genomics has lower revenue, but higher earnings than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.42	-$56.70M	-$2.31	N/A
Bionano Genomics	$28.51M	0.50	-$26.40M	-$3.02	N/A

Harvard Bioscience has a net margin of -11.86% compared to Bionano Genomics' net margin of -106.58%. Harvard Bioscience's return on equity of -33.13% beat Bionano Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
Bionano Genomics	-106.58%	-78.78%	-48.54%

Harvard Bioscience presently has a consensus target price of $6.75, indicating a potential downside of 15.84%. Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' higher possible upside, analysts clearly believe Bionano Genomics is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Harvard Bioscience beats Bionano Genomics on 8 of the 13 factors compared between the two stocks.

How does Bionano Genomics compare to Bullfrog AI?

Bionano Genomics (NASDAQ:BNGO) and Bullfrog AI (NASDAQ:BFRG) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Bullfrog AI has lower revenue, but higher earnings than Bionano Genomics. Bullfrog AI is trading at a lower price-to-earnings ratio than Bionano Genomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.50	-$26.40M	-$3.02	N/A
Bullfrog AI	$298.80K	31.23	-$6.50M	-$0.46	N/A

In the previous week, Bionano Genomics' average media sentiment score of 0.00 equaled Bullfrog AI'saverage media sentiment score.

Company	Overall Sentiment
Bionano Genomics	Neutral
Bullfrog AI	Neutral

Bionano Genomics presently has a consensus price target of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts plainly believe Bionano Genomics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bullfrog AI	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Bullfrog AI has a net margin of 0.00% compared to Bionano Genomics' net margin of -106.58%. Bionano Genomics' return on equity of -78.78% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
Bullfrog AI	N/A	-150.36%	-127.98%

11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by company insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bionano Genomics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.71, indicating that its share price is 371% less volatile than the broader market.

Summary

Bionano Genomics beats Bullfrog AI on 9 of the 14 factors compared between the two stocks.

How does Bionano Genomics compare to VivoSim Labs?

VivoSim Labs (NASDAQ:VIVS) and Bionano Genomics (NASDAQ:BNGO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

VivoSim Labs has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Bionano Genomics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

VivoSim Labs has higher earnings, but lower revenue than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than VivoSim Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoSim Labs	$112K	41.20	-$13.84M	-$4.47	N/A
Bionano Genomics	$28.51M	0.50	-$26.40M	-$3.02	N/A

Bionano Genomics has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, analysts clearly believe Bionano Genomics is more favorable than VivoSim Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

8.2% of VivoSim Labs shares are owned by institutional investors. Comparatively, 11.4% of Bionano Genomics shares are owned by institutional investors. 1.0% of VivoSim Labs shares are owned by insiders. Comparatively, 0.7% of Bionano Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bionano Genomics has a net margin of -106.58% compared to VivoSim Labs' net margin of -11,016.07%. Bionano Genomics' return on equity of -78.78% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoSim Labs	-11,016.07%	-612.23%	-177.02%
Bionano Genomics	-106.58%	-78.78%	-48.54%

In the previous week, VivoSim Labs had 3 more articles in the media than Bionano Genomics. MarketBeat recorded 3 mentions for VivoSim Labs and 0 mentions for Bionano Genomics. VivoSim Labs' average media sentiment score of 0.35 beat Bionano Genomics' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the media.

Company	Overall Sentiment
VivoSim Labs	Neutral
Bionano Genomics	Neutral

Summary

Bionano Genomics beats VivoSim Labs on 10 of the 16 factors compared between the two stocks.

How does Bionano Genomics compare to iSpecimen?

Bionano Genomics (NASDAQ:BNGO) and iSpecimen (NASDAQ:ISPC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Bionano Genomics has a beta of 1.65, meaning that its stock price is 65% more volatile than the broader market. Comparatively, iSpecimen has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Bionano Genomics has a net margin of -106.58% compared to iSpecimen's net margin of -2,445.40%. Bionano Genomics' return on equity of -78.78% beat iSpecimen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bionano Genomics	-106.58%	-78.78%	-48.54%
iSpecimen	-2,445.40%	-524.39%	-140.42%

11.4% of Bionano Genomics shares are owned by institutional investors. Comparatively, 13.6% of iSpecimen shares are owned by institutional investors. 0.7% of Bionano Genomics shares are owned by company insiders. Comparatively, 12.2% of iSpecimen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bionano Genomics presently has a consensus target price of $6.00, indicating a potential upside of 400.00%. Given Bionano Genomics' stronger consensus rating and higher probable upside, research analysts plainly believe Bionano Genomics is more favorable than iSpecimen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bionano Genomics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
iSpecimen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, iSpecimen had 1 more articles in the media than Bionano Genomics. MarketBeat recorded 1 mentions for iSpecimen and 0 mentions for Bionano Genomics. Bionano Genomics' average media sentiment score of 0.00 equaled iSpecimen'saverage media sentiment score.

Company	Overall Sentiment
Bionano Genomics	Neutral
iSpecimen	Neutral

iSpecimen has lower revenue, but higher earnings than Bionano Genomics. Bionano Genomics is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bionano Genomics	$28.51M	0.50	-$26.40M	-$3.02	N/A
iSpecimen	$1.93M	2.01	-$10.49M	-$56.44	N/A

Summary

Bionano Genomics beats iSpecimen on 9 of the 15 factors compared between the two stocks.

Get Bionano Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BNGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BNGO vs. The Competition

Export

Metric	Bionano Genomics	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.14M	$9.93B	$7.17B	$12.88B
Dividend Yield	N/A	1.46%	2.53%	8.57%
P/E Ratio	-0.40	65.01	272.99	25.40
Price / Sales	0.50	111.65	612.73	97.75
Price / Cash	N/A	26.86	77.82	52.27
Price / Book	0.45	35.98	12.85	6.17
Net Income	-$26.40M	$56.67B	$3.47B	$349.50M
7 Day Performance	2.56%	-0.83%	1.24%	-0.05%
1 Month Performance	7.14%	4.54%	5.81%	0.80%
1 Year Performance	-67.03%	26.48%	25.75%	15.62%

Bionano Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BNGO Bionano Genomics	1.8358 of 5 stars	$1.20 -3.2%	$6.00 +400.0%	-68.0%	$14.14M	$28.51M	N/A	300	Analyst Upgrade
IBAC IB Acquisition	N/A	$10.80 -0.8%	N/A	+2.9%	$54.11M	N/A	N/A	N/A	News Coverage
HBIO Harvard Bioscience	0.7473 of 5 stars	$7.51 -0.5%	$6.75 -10.1%	+68.8%	$34.18M	$87.81M	N/A	490
BFRG Bullfrog AI	0.9984 of 5 stars	$0.57 -2.9%	N/A	-59.2%	$10.49M	$120K	N/A	4	Gap Down
VIVS VivoSim Labs	0.2959 of 5 stars	$0.29 -1.0%	N/A	-88.9%	$4.34M	$130K	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BNGO) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bionano Genomics (BNGO) Competitors

BNGO vs. IBAC, HBIO, BFRG, VIVS, and ISPC

How does Bionano Genomics compare to IB Acquisition?

Summary

How does Bionano Genomics compare to Harvard Bioscience?

Summary

How does Bionano Genomics compare to Bullfrog AI?

Summary

How does Bionano Genomics compare to VivoSim Labs?

Summary

How does Bionano Genomics compare to iSpecimen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bionano Genomics (BNGO) Competitors

BNGO vs. IBAC, HBIO, BFRG, VIVS, and ISPC

How does Bionano Genomics compare to IB Acquisition?

Is IBAC or BNGO more profitable?

Do analysts prefer IBAC or BNGO?

Does the media favor IBAC or BNGO?

Do institutionals & insiders believe in IBAC or BNGO?

Which has stronger valuation & earnings, IBAC or BNGO?

Summary

How does Bionano Genomics compare to Harvard Bioscience?

Which has more volatility and risk, HBIO or BNGO?

Does the media prefer HBIO or BNGO?

Do institutionals and insiders have more ownership in HBIO or BNGO?

Which has preferable valuation & earnings, HBIO or BNGO?

Is HBIO or BNGO more profitable?

Do analysts recommend HBIO or BNGO?

Summary

How does Bionano Genomics compare to Bullfrog AI?

Which has preferable valuation & earnings, BNGO or BFRG?

Does the media refer more to BNGO or BFRG?

Do analysts recommend BNGO or BFRG?

Is BNGO or BFRG more profitable?

Do institutionals & insiders believe in BNGO or BFRG?

Which has more volatility & risk, BNGO or BFRG?

Summary

How does Bionano Genomics compare to VivoSim Labs?

Which has more risk and volatility, VIVS or BNGO?

Which has stronger valuation and earnings, VIVS or BNGO?

Do analysts prefer VIVS or BNGO?

Do insiders & institutionals believe in VIVS or BNGO?

Is VIVS or BNGO more profitable?

Does the media refer more to VIVS or BNGO?

Summary

How does Bionano Genomics compare to iSpecimen?

Which has more risk & volatility, BNGO or ISPC?

Is BNGO or ISPC more profitable?

Do institutionals & insiders have more ownership in BNGO or ISPC?

Do analysts prefer BNGO or ISPC?

Does the media favor BNGO or ISPC?

Which has stronger earnings and valuation, BNGO or ISPC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNGO vs. The Competition

Bionano Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools